Skip to main content

Soluble immune-checkpoint factors: a potential immunotherapy biomarker.

Publication ,  Journal Article
Tan, AC; Cook, SL; Khasraw, M
Published in: J Clin Invest
April 1, 2024

There is unmet need for additional biomarkers to better select patients with non-small cell lung cancer (NSCLC) that are likely to benefit from immunotherapy in order to improve patient outcomes, reduce patient toxicity, and relieve the growing burden of healthcare costs. In this issue of the JCI, Hayashi and colleagues evaluated soluble forms of the immune checkpoint molecules PD-L1, PD-1, and CTLA-4 in the plasma of patients with advanced NSCLC who had been treated with anti-PD-1/L1 therapy. The findings suggest that these soluble immune-checkpoint factors may provide a complementary biomarker to PD-L1 IHC, although application into the clinic may not be straightforward.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

April 1, 2024

Volume

134

Issue

7

Location

United States

Related Subject Headings

  • Lung Neoplasms
  • Immunotherapy
  • Immunology
  • Immunologic Factors
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Biomarkers, Tumor
  • Biomarkers
  • B7-H1 Antigen
  • 42 Health sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tan, A. C., Cook, S. L., & Khasraw, M. (2024). Soluble immune-checkpoint factors: a potential immunotherapy biomarker. J Clin Invest, 134(7). https://doi.org/10.1172/JCI179352
Tan, Aaron C., Sarah L. Cook, and Mustafa Khasraw. “Soluble immune-checkpoint factors: a potential immunotherapy biomarker.J Clin Invest 134, no. 7 (April 1, 2024). https://doi.org/10.1172/JCI179352.
Tan AC, Cook SL, Khasraw M. Soluble immune-checkpoint factors: a potential immunotherapy biomarker. J Clin Invest. 2024 Apr 1;134(7).
Tan, Aaron C., et al. “Soluble immune-checkpoint factors: a potential immunotherapy biomarker.J Clin Invest, vol. 134, no. 7, Apr. 2024. Pubmed, doi:10.1172/JCI179352.
Tan AC, Cook SL, Khasraw M. Soluble immune-checkpoint factors: a potential immunotherapy biomarker. J Clin Invest. 2024 Apr 1;134(7).

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

April 1, 2024

Volume

134

Issue

7

Location

United States

Related Subject Headings

  • Lung Neoplasms
  • Immunotherapy
  • Immunology
  • Immunologic Factors
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Biomarkers, Tumor
  • Biomarkers
  • B7-H1 Antigen
  • 42 Health sciences